| Literature DB >> 25284784 |
Shan Dong1, Michael F Walker2, Nicholas J Carriero3, Michael DiCola4, A Jeremy Willsey5, Adam Y Ye6, Zainulabedin Waqar7, Luis E Gonzalez7, John D Overton8, Stephanie Frahm4, John F Keaney9, Nicole A Teran7, Jeanselle Dea2, Jeffrey D Mandell2, Vanessa Hus Bal2, Catherine A Sullivan7, Nicholas M DiLullo7, Rehab O Khalil10, Jake Gockley11, Zafer Yuksel12, Sinem M Sertel13, A Gulhan Ercan-Sencicek14, Abha R Gupta15, Shrikant M Mane16, Michael Sheldon17, Andrew I Brooks4, Kathryn Roeder18, Bernie Devlin19, Matthew W State20, Liping Wei21, Stephan J Sanders22.
Abstract
Whole-exome sequencing (WES) studies have demonstrated the contribution of de novo loss-of-function single-nucleotide variants (SNVs) to autism spectrum disorder (ASD). However, challenges in the reliable detection of de novo insertions and deletions (indels) have limited inclusion of these variants in prior analyses. By applying a robust indel detection method to WES data from 787 ASD families (2,963 individuals), we demonstrate that de novo frameshift indels contribute to ASD risk (OR = 1.6; 95% CI = 1.0-2.7; p = 0.03), are more common in female probands (p = 0.02), are enriched among genes encoding FMRP targets (p = 6 × 10(-9)), and arise predominantly on the paternal chromosome (p < 0.001). On the basis of mutation rates in probands versus unaffected siblings, we conclude that de novo frameshift indels contribute to risk in approximately 3% of individuals with ASD. Finally, by observing clustering of mutations in unrelated probands, we uncover two ASD-associated genes: KMT2E (MLL5), a chromatin regulator, and RIMS1, a regulator of synaptic vesicle release.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25284784 PMCID: PMC4194132 DOI: 10.1016/j.celrep.2014.08.068
Source DB: PubMed Journal: Cell Rep Impact factor: 9.995